Form 4: BridgeBio Pharma Director Andrea Ellis Acquires Stock Options
SEC Form 4 Filing
Director Andrea Ellis acquired stock options for 26,014 shares of BridgeBio Pharma, Inc. on June 21, 2024.
Summary
- On June 21, 2024, Andrea Ellis, a director of BridgeBio Pharma, Inc., acquired stock options for 26,014 shares.
- The exercise price of these options is $27.36.
- The options vest in three equal annual installments starting June 21, 2024, and will be fully vested by June 21, 2027, contingent upon continued service on the board.
- Following the transaction, Ellis directly owns options for 26,014 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing related to stock option grants.
Positives
- The acquisition of stock options by a director signals confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into insider transactions, allowing investors to monitor the actions of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's success.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date of the stock option acquisition. |
| 06/21/2024 | First vesting date for the stock options. |
| 06/21/2027 | Date when all stock options will be fully vested. |
| 06/20/2034 | Expiration date of the stock options. |
| 06/25/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.